Ensysce Biosciences Inc. [ENSC] is 1.06% higher this YTD. Is it still time to buy?


Ensysce Biosciences Inc. [NASDAQ: ENSC] stock went on an upward path that rose over 18.16% on Thursday, amounting to a one-week price increase of more than 7.47%. The company report on January 5, 2022 that Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with novel technology platforms that may provide new hope for those in severe pain, today announced management’s participation in the H.C. Wainwright BIOCONNECT Conference being held virtually January 10-13, 2022.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


An on-demand presentation from the H.C. Wainwright conference will be available through Ensysce’s Investor Relations website at https://ir.ensysce.com/ beginning January 10, 2022, at 7:00am ET.

Over the last 12 months, ENSC stock dropped by -60.42%.

The market cap for the stock reached $116.75 million, with 6.22 million shares outstanding. Compared to the average trading volume of 6.78M shares, ENSC stock reached a trading volume of 20677075 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Ensysce Biosciences Inc. [ENSC]:

The Average True Range (ATR) for Ensysce Biosciences Inc. is set at 0.95 The Price to Book ratio for the last quarter was 15.83, with the Price to Cash per share for the same quarter was set at 0.00.

ENSC Stock Performance Analysis:

Ensysce Biosciences Inc. [ENSC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.47. With this latest performance, ENSC shares gained by 48.90% in over the last four-week period, additionally sinking by -59.82% over the last 6 months – not to mention a drop of -60.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENSC stock in for the last two-week period is set at 60.00, with the RSI for the last a single of trading hit 61.08, and the three-weeks RSI is set at 58.92 for Ensysce Biosciences Inc. [ENSC]. The present Moving Average for the last 50 days of trading for this stock 2.82, while it was recorded at 4.37 for the last single week of trading, and 7.29 for the last 200 days.

Insight into Ensysce Biosciences Inc. Fundamentals:

Return on Total Capital for ENSC is now -1.47, given the latest momentum, and Return on Invested Capital for the company is 4.63. Return on Equity for this stock inclined to 4.66, with Return on Assets sitting at 4.12.

Ensysce Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.

>> 7 Top Picks for the Post-Pandemic Economy <<

Ensysce Biosciences Inc. [ENSC] Insider Position Details

There are presently around $13 million, or 14.50% of ENSC stock, in the hands of institutional investors. The top three institutional holders of ENSC stocks are: HG VORA CAPITAL MANAGEMENT, LLC with ownership of 2,462,500, which is approximately -28.881% of the company’s market cap and around 33.90% of the total institutional ownership; STIFEL FINANCIAL CORP, holding 323,342 shares of the stock with an approximate value of $1.3 million in ENSC stocks shares; and FOUNDERS FUND ILL MANAGEMENT, LLC, currently with $0.58 million in ENSC stock with ownership of nearly New of the company’s market capitalization.

Positions in Ensysce Biosciences Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 14 institutional holders increased their position in Ensysce Biosciences Inc. [NASDAQ:ENSC] by around 658,762 shares. Additionally, 3 investors decreased positions by around 1,025,027 shares, while 0 investors held positions by with 1,471,586 shares. The mentioned changes placed institutional holdings at 3,155,375 shares, according to the latest SEC report filing. ENSC stock had 14 new institutional investments in for a total of 658,762 shares, while 1 institutional investors sold positions of 1,212 shares during the same period.